Antifungal pill may change how lung cancer drug works

NCT ID NCT02157883

Completed Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how itraconazole, an antifungal medication, affects the levels of the lung cancer drug AZD9291 in the body. It involved 39 adults with advanced EGFR-mutant non-small cell lung cancer whose disease had worsened after previous treatments. The goal was to understand drug interactions, not to test a cure, and results help guide safe dosing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED (INOPERABLE) NON SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED (INOPERABLE) NON SMALL CELL LUNG CANCER ADVANCED NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Research Site

San Diego, California, 92123, United States
Research Site

Cleveland, Ohio, 44106, United States
Research Site

Edegem, 2650, Belgium
Research Site

Ghent, 9000, Belgium
Research Site

Amsterdam, 1066 CX, Netherlands
Research Site

Maastricht, 6229 HX, Netherlands
Research Site

Rotterdam, 3015 GD, Netherlands
Research Site

lJongno-gu, 03080, South Korea
Research Site

Seongnam-si, 13620, South Korea
Research Site

Seoul, 03722, South Korea
Research Site

Seoul, 05505, South Korea
Research Site

Seoul, 06351, South Korea
Research Site

Taipei, 10002, Taiwan
Research Site

Taipei, 11217, Taiwan
Research Site

London, SE1 9RT, United Kingdom
Research Site

Manchester, M20 4BX, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.